Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Zevra Therapeutics, Inc. (ZVRA) – Form 4 filing dated 06/24/2025
The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded “M,” indicating a conversion of a derivative security rather than an open-market purchase or sale.
Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.
No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.